Migraine Australia has been advised that discussions between Novartis and the Australian Government have not reached an agreement to list Aimovig® (erenumab) on the Pharmaceutical Benefits Scheme (PBS).
This news will be disappointing for many in our migraine community. We're assured that Novartis recognises the financial burden for patients and remains committed to exploring alternative pathways to support access. As such, Novartis is actively working toward an affordable private market solution for Australian patients. It will also continue to be available via private prescription, at an estimated cost of $750–$850 per month.
We encourage patients to speak with their treating doctor to explore all available treatment options.
As a reminder, PBS rules changed in November 2024 to allow General Practitioners, in consultation with specialists, to start patients on new migraine management medications. GPs can also prescribe these medications privately without specialist initiation, though cost remains a significant barrier for many.
CGRP medications – a new class of targeted preventive therapies – have been a major breakthrough for people living with migraine since their introduction in 2018. They are now considered a first-line treatment for migraine prevention. Three CGRP therapies – Ajovy®, Emgality®, and Vyepti® – are currently PBS-listed for eligible patients, saving thousands of dollars annually.
Migraine Australia remains committed to advocating for improved, affordable access to these life-changing treatments for all Australians living with migraine.